Document Type

Article

Publication Date

12-25-2023

Comments

This article is the author’s final published version in the Journal of Orthopaedic Research, Volume 42, Issue 3: 2023 ORS International Consensus Meeting and Related Research on Musculoskeletal Infection, Mar 2024, Pages 512-517.

The published version is available at https://doi.org/10.1002/jor.25774. Copyright © 2024 The Authors. Journal of Orthopaedic Research® published by Wiley Periodicals LLC on behalf of Orthopaedic Research Society.

Publication made possible in part by support through a transformative agreement between Thomas Jefferson University and the publisher.

Abstract

Antimicrobial strategies for musculoskeletal infections are typically first developed with in vitro models. The In Vitro Section of the 2023 Orthopedic Research Society Musculoskeletal Infection international consensus meeting (ICM) probed our state of knowledge of in vitro systems with respect to bacteria and biofilm phenotype, standards, in vitro activity, and the ability to predict in vivo efficacy. A subset of ICM delegates performed systematic reviews on 15 questions and made recommendations and assessment of the level of evidence that were then voted on by 72 ICM delegates. Here, we report recommendations and rationale from the reviews and the results of the internet vote. Only two questions received a ≥90% consensus vote, emphasizing the disparate approaches and lack of established consensus for in vitro modeling and interpretation of results. Comments on knowledge gaps and the need for further research on these critical MSKI questions are included.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

38146070

Language

English

Share

COinS